The Vendor Blog as a Labeling Surface
Updated August 25, 2026
In warning letter 695156-12102024, dated December 10, 2024, FDA quoted a blog post published on Prime Peptides' own domain in the same manner as product labeling. The post was a listicle with pros-and-statistics framing; its placement on the seller's domain, not its format, decided how the agency read it.
A citation from the blog, not the shop
Vendor sites in this market typically split into a store section and an editorial section — product listings on one side, articles on the other. The letter to Prime Vitality, Inc. dba Prime Peptides of Santa Barbara, California, operator of primepeptides.co, documents that the split carried no evidentiary weight. In its October 2024 review of the site, FDA quoted a post from the company's on-domain blog exactly as it quoted the product pages, and placed it in the letter as evidence of intended use under 21 CFR 201.128. The letter as a whole is documented at this index's Prime Peptides letter record.
The record of the citation
| Surface | A blog post on the storefront's own domain |
|---|---|
| Format | Listicle-style, with pros-and-statistics framing for compounds sold on the site |
| How the letter used it | Quoted in the same manner as the product listings — as labeling evidence bearing on intended use |
| What made it attributable | Publication on the seller's domain; no separate attribution step was needed |
| Wording | Not reproduced here; the letter is public and linked under Sources |
The domain as one document
The method is simple to state: for intended-use purposes, the agency read the domain as one document. An article does not carry a price button, and editorial pages often sit under a different template and a different tone than the catalog. None of that registered in the letter. Copy about the compounds, published by the seller, on the seller's site, was the seller's labeling — whichever section of the site held it. The December 2024 batch as a whole extended the review past product pages in two directions at once: inward across the domain, as this record shows, and outward to the seller's social accounts under the purchase-direction attribution.
The same letter's other surfaces
The blog citation is one of three evidence methods this index records from letter 695156-12102024. The others: a YouTube video whose on-screen text and spoken narration were both quoted, at the video-evidence page, and outcome-bearing customer reviews the seller reposted, at the review-amplification page. The batch context — four letters to research-peptide sellers on one date — is tabulated at the December 10, 2024 batch record.
Where the boundary moved next
Fifteen months later the same reading crossed the domain line entirely. In the March 31, 2026 batch, one letter reviewed a seller's site "which links to your community forum" and quoted material hosted on that third-party platform as the seller's own labeling — the record is at the linked-content evidence page. On-domain articles in 2024, linked off-domain content in 2026: the surface widened, the attribution logic did not change.
A blog is also the surface where the free-speech objection feels strongest, because an article reads less like a sales pitch than a product page does. FDA's position is that reading an article as evidence of intended use is not a restriction on publishing it, and the agency set that out in a 2021 rulemaking: the First Amendment and intended-use evidence.
Mechanics and current status
The letter's mechanics match the batch: email delivery, 15 working days demanded for a response, escalation language naming "seizure and injunction," public posting on December 17, 2024. No close-out letter or follow-on action for this recipient has been found as of this page's dateline; the outcome is unknown and is recorded here as unknown. The document type is explained at the warning-letter explainer; the recipient's entity record is held in the vendor index.
Sources
- FDA Warning Letter, Prime Vitality, Inc. dba Prime Peptides, 695156-12102024. fda.gov
- FDA Warning Letters index. fda.gov
- FDA Roundup, December 17, 2024. fda.gov
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.